Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant Enterococci and Clostridium difficile infections

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 61-67

  Mendez, Marisa N ^a   Gibbs, Laurel ^c   Jacobs, Richard A ^b   McCulloch, Charles E ^b   Winston, Lisa ^b   Guglielmo, B Joseph ^a,d  

^a School of Pharmacy   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial prescribing; Clostridium difficile; Drug shortages; Piperacillin tazobactam; Vancomycin resistant enterococci

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFAZOLIN; CEFEPIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; COLITIS; DEMOGRAPHY; DRUG UTILIZATION; HUMAN; NONHUMAN; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CALIFORNIA; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG UTILIZATION; ENTEROCOCCUS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; PENICILLANIC ACID; PIPERACILLIN; PRESCRIPTIONS, DRUG; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 30544449215     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.61     Document Type: Review

References (11)

1. American Society of Health-System, Pharmacists. Drug product shortages management resource center home page. Available from http://www.ashp.org/ shortage. Accessed May 25, 2005.
2. Anonymous. Provisional observations oh drug product shortages: effects, causes, and potential solutions. Summary of a stakeholders' meeting on drug shortages convened by the American Medical. Association and the American Society of Health-System Pharmacists. Am J Health-Syst. Pharm 2002;59:2173-82.
3. Strausbaugh LJ, Jernigan DB, Liedtke LA, for the Infectious Diseases Society of America Emerging Infections Network. National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases. Society of America emerging infections network. Clin Infect Dis 2001;33:1495-501.
4. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-5.
5. Alston WK, Ahern JW. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 2004;53:549-51.
6. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;54:168-72.
7. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF III. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control 2004;32:462-9.
8. Bartleft JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
9. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
10. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003;51:1339-50.
11. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimcrobial resistance problem. Clin Infect Dis 2004;38:646-8.